Ep. 399 - Key themes from Jefferies. Plus: U.K. regulatory innovation
Ep. 399 - Key themes from Jefferies. Plus: U.K. regulatory innovation
Speed to patients and cross-border collaboration dominated conversations at London Life Sciences Week, even as investors on both sides of the Atlantic grapple with the COINS Act’s restrictions on taking equity in China-based companies. In a special live edition of the BioCentury This Week podcast, recorded at the 4th Biotech CEO & Investor Reception in London, Stephen Hansen is joined by Jackie Mulryne of Morgan Lewis, WuXi AppTec co-CEO Steve Yang, and BioCentury’s Simone Fishburn and Josh Berl
AI 伴隨問答
針對這篇報導有疑問?可直接點選快捷問題或向 AI 追問背景脈絡與技術細節:
Podcast 專家音訊節目
收錄於 888news Podcast 智庫專區,包含精華摘要與上市公司即時行情
Speed to patients and cross-border collaboration dominated conversations at London Life Sciences Week, even as investors on both sides of the Atlantic grapple with the COINS Act’s restrictions on taking equity in China-based companies. In a special live edition of the BioCentury This Week podcast, recorded at the 4th Biotech CEO & Investor Reception in London, Stephen Hansen is joined by Jackie Mulryne of Morgan Lewis, WuXi AppTec co-CEO Steve Yang, and BioCentury’s Simone Fishburn and Josh Berlin to share key takeaways from the week. The panel discusses MHRA’s push under new CEO Lawrence Tallon to make the U.K. a hub for regulatory innovation, momentum behind non-animal methods (NAMs), and why AI-driven drug design is creating surging demand for automated wet lab capacity. They also explore why European investors see little advantage from COINS, and the split in reactions to Isomorphic Labs’ reported $5 billion raise. View full story: https://www.biocentury.com/article/661686 #LondonLifeSciencesWeek #RegulatoryInnovation #AIDrugDiscovery #COINSAct #BiotechInvesting 0:00 Introduction 2:13 U.K. Regulatory Innovation 15:10 AI Needs Wet Labs 17:56 COINS Act and Investors 24:13 Isomorphic Valuation Debate To submit a question to BioCentury’s editors, email the BioCentury This Week team at podcasts@biocentury.com. Reach us by sending a text